Discoid lupus erythematosus precipitated by topical diphencyprone immunotherapy for alopecia areata

Foo, Hui Ling; Lee, Joyce Siong See; Wang, Etienne Cho Ee

doi:10.1016/j.jdcr.2020.05.037

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the signifcant publication bias, estimates of the incidence of adverse efects may not be accurate. In addition to the adverse efects listed above, DPCP may cause some rare but serious side efects such as erythema multiforme major [14] and discoid lupus erythematosus [15] in some cases.…”

Section: Adverse Efectsmentioning

confidence: 99%

The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systemic Review and Meta‐Analysis

Zhu,

Qiao,

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

Background and Objective. Diphenylcyclopropenone topical immunotherapy is widely used in the treatment of alopecia areata. However, previous studies have shown significant differences in its efficacy. We conducted this systemic review and meta-analysis to investigate the efficacy, safety, and recurrence rate of diphenylcyclopropenone topical immunotherapy for alopecia areata. Methods. Literatures related to diphenylcyclopropenone topical immunotherapy for alopecia areata between January 1st, 2002, and July 2nd, 2022, were searched in the following databases: PubMed, Embase, Cochrane Library, Sinomed, WanFang Data, and Chinese Medical Journal Network. Results. This meta-analysis included a total of 40 moderate to high quality studies involving 3,002 patients. The overall rate of any hair regrowth was 69%, and the overall rate of complete hair regrowth was 23%. The rate of any hair regrowth in patients with alopecia totalis or alopecia universalis was 42%, and the rate of any hair regrowth in patients with other types of alopecia areata was 75%. Common side effects were mild contact dermatitis (36%), severe contact dermatitis (31%), regional lymphadenopathy (22%), hyperpigmentation (22%), and hypopigmentation (7%). The recurrence rate was 37%. Conclusion. Diphenylcyclopropenone topical immunotherapy is an effective treatment for various types of alopecia areata, and most of its common side effects are acceptable.

show abstract

Section: Adverse Efectsmentioning

confidence: 99%

The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systemic Review and Meta‐Analysis

Zhu,

Qiao,

et al. 2023

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Except for the expected adverse reactions, that is, contact dermatitis [148,[163][164][165] or lymphadenopathy [166][167][168], there are some rare or even serious adverse events reported. These include urticaria [169][170][171][172][173][174][175][176][177], depigmentation [155,156,160], vitiligo [150-154, 157-159, 178], erythema multiforme [179][180][181][182][183], discoid lupus erythematosus [184,185], angioedema [186,187], nickel sensitivity [188], allergic contact dermatitis from dyes in wigs [189], acquired hair curling [190], hair pigmentary changes [191], psoriatic koebnerization [192], pityriasis lichenoides [193], dyspepsia [173], epidermolysis bullosa acquisita [194], and anaphylaxis [195]. In addition, there are a few reports documenting sensitization to the medical staff that handle the chemical compound [196][197][198][199][200][201].…”

Section: Adverse Effects and Safety Concerns Of Topical Immunotherapymentioning

confidence: 99%

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Lai

Tsai

2022

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

For decades, contact immunotherapy with dinitrochlorobenzene, diphencyprone, and squaric acid dibutylester has played an important role in both clinical practice and scientific research. It is listed as the first-line treatment for extensive alopecia areata and was more recently approved for melanoma treatment as an orphan drug in the USA. Moreover, owing to the relative low cost and safety, topical immunotherapy has also been used in many infectious, neoplastic, and inflammatory dermatological diseases. It is especially valuable in vulnerable groups, for cosmetic/pain sensitive areas, or for multiple lesions. In this review, we summarize the current evidence supporting the use of contact immunotherapy for treatment of skin diseases, from articles collected from PubMed database. Owing to space limitation and already numerous studies focusing on alopecia areata, we include only skin diseases other than alopecia areata. In addition to diseases that have been reported to be treated by contact immunotherapy, the hypothesized mechanism, prognosis prediction, efficacy, and safety of these topical agents are discussed.

show abstract

Diphencyprone/triamcinolone

2020

Reactions Weekly

View full text Add to dashboard Cite

Discoid lupus erythematosus precipitated by topical diphencyprone immunotherapy for alopecia areata

Cited by 4 publications

References 7 publications

The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systemic Review and Meta‐Analysis

The Efficacy, Safety, and Recurrence Rate of Diphenylcyclopropenone Topical Immunotherapy for Alopecia Areata: A Systemic Review and Meta‐Analysis

Use of Contact Immunotherapy in the Treatment of Skin Diseases Other than Alopecia Areata

Diphencyprone/triamcinolone

Contact Info

Product

Resources

About